Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study
Digestive and Liver Disease · 2025
DOI: 10.1016/j.dld.2025.09.032 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Digestive and Liver Disease, 2025. Verfasst von Ahmad Albshesh und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Sheba Medical Center Israel; Faculty of Medical & Health Sciences, Tel- Aviv University, Tel-Aviv, Israel. Electronic…. Hauptthemen laut MEDLINE: Ustekinumab, Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Withholding Treatment. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Sheba Medical Center Israel; Faculty of Medical & Health Sciences, Tel- Aviv University, Tel-Aviv, Israel. Electronic address: Ahmad.albshesh@gmail.com.
- Department of Oncological Gastroenterology, The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland; Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Me…
- Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, L. Go A. Gemelli 8, 00168 Rome, Italy; UOS Gastroenterologia, Ospedale Isola Tiberina Gemelli Isola, Roma, Italy.
- Service de Gastroentérologie, CHU Bicêtre, Assistance Publique-Hôpitaux de Paris, CESP INSERM-U1018, Université Paris Saclay, France.
- Department of Gastroenterology, Sheba Medical Center Israel; Faculty of Medical & Health Sciences, Tel- Aviv University, Tel-Aviv, Israel; The Abraham and Sonia Rochlin IBD Unit, Department of Gastroenterology, Emek Med…
- Department of Gastroenterology, Dietetics and Internal Medicine, Poznań University of Medical Sciences, University Clinical Hospital, Poznan, Poland.
Zitieren
APA
Albshesh, A., Kucha, P., Pugliese, D., Amiot, A., Mahajna, H., Eder, P., Savarino, E. V., Vavricka, S., Castiglione, F., Imperatore, N., Krznaric, Z., Abitbol, C. M., Hen, O., Zaborowska, M., Carbonnel, F., Cuccia, G., Lorenzon, G., Zittan, E., Zagórowicz, E., …, & Kopylov, U. (2025). Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study. Digestive and Liver Disease. https://doi.org/10.1016/j.dld.2025.09.032
Vancouver
Albshesh A, Kucha P, Pugliese D, Amiot A, Mahajna H, Eder P, et al. Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study. Digestive and Liver Disease. 2025. doi:10.1016/j.dld.2025.09.032
BibTeX
@article{Albshesh2025,
author = {Albshesh, Ahmad and Kucha, Piotr and Pugliese, Daniela and Amiot, Aurélien and Mahajna, Hussein and Eder, Piotr and Savarino, Edoardo Vincenzo and Vavricka, Stephan and Castiglione, Fabiana and Imperatore, Nicola and Krznaric, Zeljko and Abitbol, Chaya Mushka and Hen, Or and Zaborowska, Marta and Carbonnel, Franck and Cuccia, Giuseppe and Lorenzon, Greta and Zittan, Eran and Zagórowicz, Edyta and Maniero, Daria and Ben-Horin, Shomron and Kopylov, Uri},
title = {Relapse rate following withdrawal of vedolizumab and ustekinumab in patients with inflammatory bowel disease - a multicenter retrospective controlled study. The VEDUST-EXIT Study},
journal = {Digestive and Liver Disease},
year = {2025},
doi = {10.1016/j.dld.2025.09.032}
}
EUVIMED